Regeneron receives FDA approval for aflibercept injection 8mg for treatment of wet AMD, DME, DR
August 19th 2023According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.
Paul Hahn, MD, PhD, shared insights on research comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy presented at the 2023 ASRS annual meeting.
BREAKING NEWS: FDA approves lotilaner ophthalmic solution 0.25% for treatment of Demodex blepharitis
July 25th 2023According to Tarsus Pharmaceuticals, lotilaner ophthalmic solution 0.25% is the first approved therapeutic for Demodex blepharitis, and has demonstrated efficacy across multiple clinical measures of disease.
AI used to advance drug delivery system for glaucoma and other chronic diseases
June 2nd 2023The project, a collaboration with researchers from the University of Maryland, holds promise for advancing new and more tolerable drug treatments for common chronic blinding eye diseases, including glaucoma and macular degeneration.
New FDA blood donor recommendations could ease restrictions on cornea donations from queer men
June 1st 2023The move could result in changes to guidelines that currently prohibit cornea donations from gay or bisexual men who have had sex with another man in the last 5 years of their life. There's no indication as to whether other queer communities—such as transgender women or nonbinary donors—will be impacted.
ASCRS 2023: Protecting against eye injuries in sports
Lori Pacheco, RN, CRNO, discussed sports-related eye injuries and how to prevent them at the 2023 ASCRS annual meeting in San Diego.
ASCRS 2023: Companies presenting clinical data and technology at annual meeting
May 4th 2023Eyecelerator kicks off today as the American Society of Cataract and Refractive Surgery will host this year’s ASCRS and ASOA Annual Meeting in San Diego, California, beginning on Friday. ViaLase Inc., Aurion Biotech among companies presenting at the annual meeting.
ARVO 2023: Human donor tissue to identify mechanism of retinal pigment epithelium death
Deborah Ferrington, PhD, shares a brief overview of her presentation on identifying the mechanism responsible for the death of the retinal pigment epithelium.
ARVO 2023: Lexitas presents its modified NEI scale
Andrew Pucker, OD, MS, PhD, FAAO, and George Magrath, MD, discuss Lexitas Pharma Services' work on modification of the National Eye Institute's corneal fluorescein staining scale.
ARVO 2023: Managing myopia progression with low concentration atropine
Mark Bullimore, PhD, MCOptom, shares a brief overview of her presentation on myopia management by slowing progression with low concentration atropine.
Ophthalmology group to pay nearly $3 million to resolve optometrist referral kickback allegations
March 29th 2023The U.S. Attorney' Office Eastern District of Texas reported Kleiman Evangelista Eye Centers has agreed to pay $2,902,505 to resolve False Claims Act allegations that it offered and paid kickbacks to optometrists.